What Is MUSIC G-MINOR?
The Genomics in Michigan Impacting Observation or Radiation (G-MINOR) project aims to determine the impact of a new test (Decipher) in regards to treatment decisions for men who had a radical prostatectomy (removal of the prostate).
The Decipher test uses genetic information from a sample of prostate tissue to measure how likely prostate cancer should come back following a prostatectomy.
G-MINOR’s goal is to help doctors under-stand the health and function of individuals after surgery and help determine if additional treatment is needed.
- Decipher & CAPRA-S Score
- Who can participate?
- How GMINOR Works
- Download Brochure
- Contact Us About G-MINOR
The Decipher test examines the activity of genes in prostate cancer cells and provides a score that estimates the likelihood that a patient’s cancer will spread. The score may help separate individuals into low or high risk groups to help guide the need for additional treatment. In addition to the score, the cancer tissue will be used for discovery of genes that may help in diagnosing, preventing, or treating prostate cancer. This de-identified information will also help to improve the care of other men diagnosed with prostate cancer throughout the state of Michigan.
The CAPRA-S score uses clinical factors such as preoperative prostate specific antigen (PSA), pathologic tumor stage, Gleason score, surgical margin status, and lymph node status to determine a patient’s risk of prostate cancer recurrence.
The score is reported on a scale of 0 to 12 and can also be used to separate individuals into different risk groups to help determine the need for additional treatment. A score of 0-2 is considered low-risk, 3-5 is intermediate-risk, and 6-12 is high-risk for future cancer recurrence.
Patients with prostate cancer who have undergone a radical prostatectomy at a participating site in MUSIC. In addition, patients must also satisfy each of the following criteria:
- Achieved post-RP PSA less than 0.1 ng/mL
- T3 or T4 pathology staging OR positive surgical margins (or both)
- Are currently within 1 year of surgery
After consent, the patient will be immediately enrolled into the study. A sample of tissue from the prostatectomy will be sent to a lab and the patient will be randomized into one of two trial pathways.
Pathway one utilizes the Cancer of the Prostate Risk Assessment post-surgical (CAPRA-S) score alone to help the patient and doctor make a decision to proceed with either observation or post-operative radiation therapy. In Pathways two, the patient and doctor will use both the Decipher test and the CAPRA-S score to guide the post-operative decision.
Patients are also required to complete MUSIC Patient Reported Outcomes (PRO) questionnaires prior to their surgery and at 3, 6, 12, and 24 months after surgery.
The questionnaires will allow for a better understanding of changes in health and function after surgery.
If you are a patient and wish to learn more about MUSIC G-MINOR, please click on the following link which provides a patient brochure on the MUSIC G-MINOR project.
If you have further questions or concerns regarding G-MINOR, please contact the MUSIC Coordinating Center at 855.456.2035 or email@example.com.